Madrigal Pharmaceuticals, Inc. (MDGL)
587.88
-1.59
(-0.27%)
USD |
NASDAQ |
Dec 30, 09:39
Madrigal Pharmaceuticals EPS Diluted (Quarterly): -5.079 for Sept. 30, 2025
EPS Diluted (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
EPS Diluted (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
EPS Diluted (Quarterly) Benchmarks
| Amgen, Inc. | 5.934 |
| Eli Lilly & Co. | 6.211 |
| Alnylam Pharmaceuticals, Inc. | 1.840 |
| Amicus Therapeutics, Inc. | 0.0558 |
| Insmed, Inc. | -1.747 |
EPS Diluted (Quarterly) Related Metrics
| Net Income (Quarterly) | -114.19M |
| Revenue (Quarterly) | 287.27M |
| Total Expenses (Quarterly) | 401.46M |
| Enterprise Value | 12.62B |
| Gross Profit Margin (Quarterly) | 93.57% |
| Profit Margin (Quarterly) | -39.75% |
| Earnings Yield | -2.21% |
| Normalized Earnings Yield | -2.198 |